Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.28 USD +8.47% Intraday chart for Ocugen, Inc. -3.03% +122.61%
04-22 Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating MT
04-22 Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Rise Friday Afternoon
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Ocugen to Restate Financial Statements; Shares Tumble
Ocugen Provides Business Update
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease
Sector Update: Health Care Stocks Steady Premarket Monday
Sector Update: Health Care Stocks Ease Late Afternoon
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders
Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.
  5. Other languages